22 04 13 Asian Test

CS MEDICA has finalized THC test at PPB level on their Cannasen®CBD products to comply with the strict regulations on the Asian market

CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the Company has now finalised the Parts-per-billion (PBB) level THC test on their CANNASEN® CBD products,  showing no trace of THC. Hong Kong, Thailand, Malaysia, and Japan are the countries that have legalized CBD products and with the PPB THC test results, CS MEDICA is now able to sell CANNASEN® CBD products in those countries.

In preparation for targeting the Asian market, CS MEDICA has performed a “1/billion no trace of THC” (PPB) test of their CANNASEN®CBD products to comply with the regulations of Asia, which currently has legalized CBD products in Hong Kong, Thailand, Malaysia, and Japan. Where Europe requires a THC level below 0,02%(plant), the Dangerous Drugs Ordinance (DDO) of Asia requires a 0,00% level of THC currently messured by PPB test level 0,000000001(product).

The PPB THC analysis of the CANNASEN® CBD product line has been performed by the University of Naples Federico II, who certifies the PPB test by a quantitative analysis of cannabinoids and metabolites: CBDA, CBGA, CBG, CBD, D9-THC and acid D9-THC measured by ultra-high-performance liquid chromatography coupled with high-solution mass spectrometry (UHPLC Q-Orbitrap HRMS). The PPB test found no traceable THC or below 1 PPB THC in the following CANNASEN® CBD products:

  • Cannasen®CBD Arthritis Gel
  • Cannasen®CBD Psoriasis Gel
  • Cannasen®CBD Anti-Hair loss serum
  • Cannasen®CBD Pain Patch
  • Cannasen®CBD Protective Nasal Gel
  • Cannasen®CBD PSOR + ATOPIC Lotion
  • Cannasen®CBD Wound Gel

CS MEDICA now awaits the final approval from Hong Kong customs, before a test sale can be established in Hong Kong. Hence the company will extend the Asian area to also include the other countries, with cannabis products legalized (Thailand, Malaysia, and Japan).

With the PPB test successfully finalized CS MEDICA will be at the forefront of the very strict cannabis medical market of Asia, where illegal CBD products are currently being removed from the market, by Hong Kong customs.  Since mid-January, Hong Kong customs have initiated a special operation under the codename “Wind Rider”, targeting cannabidiol (CBD) products containing tetrahydro-cannabinol (THC). The “Wind Rider” operation so far resulted in the seizing of about 25 000 items of CBD products from seven retail shops. The seized products containing THC included CBD oil, skincare products and pet treats with a total estimated market value of about $14,6 million.

With the successfully performed THC PPB test, CS MEDICA now complies with the very strict requirements of DDO and can sell the CANNASEN® CBD product line in Asia.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.